Given the substantial risks of substance misuse by prisoners, long-acting injectable buprenorphine should be adopted as ‘best practice’ treatment in Australian prison populations.
MundtAPBaranyiGGabryschC, et al.Substance use during imprisonment in low- and middle-income countries. Epidem Rev2018; 40(1): 70–81.
2.
LaranceBMattickRDegenhardtL, et al.Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Drug Alcohol Rev2011; 30: 236–245.
3.
CunninghamE BHajarizadehBAminJ, et al.Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: the HITS-p study. Int J Drug Policy2018; 54: 18–25
4.
KinnerSJenkinsonRGouillouM, et al.High-risk drug-use practices among a large sample of Australian prisoners. Drug Alcohol Depend2012; 126: 156–160.
5.
WhiteNAliRLaranceB, et al.The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine–naloxone film. Drug Alcohol Rev2016; 35: 76–82.
6.
BretañaN ABoelenLBullR, et al.Transmission of hepatitis C virus among prisoners, Australia, 2005–2012. Emerg Infect Dis2015; 21(5): 762–774.
7.
RunnegarN. Serious bacterial infections requiring hospitalisation of Queensland correctional centre prisoners. (in preparation)
8.
KeenCYoungJ TBorschmannR, et al.Non-fatal drug overdose after release from prison: a prospective data linkage study. Drug Alcohol Depend2020; 206: 107707
9.
MerrallE L CKariminiaABinswangerIA, et al.Meta-analysis of drug-related deaths soon after release from prison. Addiction2010; 1059: 1545–1554.
10.
HåkanssonABerglundM. Risk factors for criminal recidivism - a prospective follow-up study in prisoners with substance abuse. BMC Psychiatry2012; 12: 111.
11.
WinterRYoungJStoovéM, et al.Resumption of injecting drug use following release from prison in Australia. Drug Alcohol Depend2016; 168: 104–111.
12.
GisevNLarneySDegenhardtL, et al.Determining the impact of opioid substitution therapy upon mortality and recidivism among prisoners: a 22 year data linkage study. Trends Issues Crime Criminal Justice. Canberra: Australian Institute of Criminology, 2014.
13.
WinterRJStooveMAgiusP, et al.Injecting drug use is an independent risk factor for reincarceration after release from prison: A prospective cohort study. Drug Alcohol Rev2019; 38: 254–263.
14.
MooreKERobertsWReidWH, et al.Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review. J Subst Abuse Treat2019; 99: 32–43.
15.
MarsdenJStillwellGJonesH, et al.Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. Addiction2017; 112: 1408–1418.
16.
LarneyS.GisevN.FarrellM, et al.Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study. BMJ Open2014; 4: e004666.
17.
DegenhardtLLarneySKimberJ, et al.The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction2014; 1098: 1306–1317.
18.
GisevNShanahanMWeatherburnDJ, et al.A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence. Addiction2015; 110: 1975–1984.
19.
KomalasariRWilsonSHawS. A systematic review of qualitative evidence on barriers to and facilitators of the implementation of opioid agonist treatment (OAT) programmes in prisons. Intern J Drug Policy2021; 87: 102978.
20.
SoykaM. Novel long-acting buprenorphine medications for opioid dependence: current update. Pharmacopsychiatry2021; 54: 18–22.
21.
LeeJDMaloneMMaloneM, et al.Comparison of treatment retention of adults with opioid addiction managed with extended-release buprenorphine vs daily sublingual buprenorphine-naloxone at time of release from jail. JAMA Open2021; 4(9): e2123032. DOI:10.1001/jamanetworkopen.2021.23032
22.
LofwallMRWalshSLNunesEV, et al.Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med2018; 178(6): 764–773.
23.
FrostMBaileyGLLintzerisN, et al.Long-term safety of a weekly and monthly sub-cutaneous buprenorphine depot (CAM2038) in the treatment of adult outpatients with opioid use disorder. Addiction2019; 114(8): 1416–26.
24.
HaightBRLearnedSMLaffontCM, et al.Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2019; 393: 778–790.
25.
ChaappuyMTrojakBNubukpoP, et al.Prolonged-release buprenorphine formulations: Perspectives for clinical practice. Therapies2020; 75: 397–406.
26.
DunlopAJWhiteBRobertsJ, et al.Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings is safe, effective and cost effective. Addiction2021; Epub ahead of print.. DOI: 10.1111/add.15627
27.
LarneySDolanK. A literature review of international implementation of opioid substitution treatment in prisons: Equivalence of care?Eur Addict Res2009; 15: 107–112.
28.
BrezelERPowellTFoxAD. An ethical analysis of medication treatment for opioid use disorder for persons who are incarcerated. Substance Abuse2020; 41: 150–154.
29.
CarrollAEllisAAboudA, et al.No involuntary treatment of mental illness in Australian and New Zealand prisons. J Foren Psychiat Psychol2021; 32: 1–28.
30.
ChappuyMMerouehFTrojakB, et al.Readiness to try extended-released buprenorphine and related factors of interest: comparison between incarcerated and non-incarcerated subjects with opioid use disorder. Patient Prefer Adherence2021; 15: 1259–1267.
31.
NealeJTompkinsCNEStrangJ. Prolonged-release opioid agonist therapy: qualitative study exploring patients views of 1-week. 1-month and 6-month buprenorphine formulations. Harm Reduct J2019; 16: 25.
32.
LaranceBDegenhardtLGrebelyJ, et al.Perceptions of extended release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. Addiction2019; 115: 1295–1305
